2022 PIPELINE CONFERENCE

June 5-6, 2022 Santa Clara Marriott Santa Clara, California

Sunday, June 5

- 7:00-8:00 Breakfast and Registration
- 8:00-8:15 Welcome and Introduction Jacqueline French, MD, Chief Medical and Innovation Officer, Epilepsy Foundation R. Edward Hogan, MD, President, AES Helen Cross, MD, President, ILAE

SESSION I: IMPACT OF COVID ON CLINICAL TRIALS

- Moderator: Kimford Meador, MD
- 8:15-8:20 Patient/Caregiver Perspective Kim Nye, TESS Research Foundation
- 8:20-8:50 Panel Discussion: Is COVID helping or hurting drug development? R. Edward Hogan, MD Elaine Wirrell, MD Kathryn Davis, MD Lilly Frohlich, MPH Kim Nye
- 8:50-9:05 Remote Trial Design IQVIA Penny Randall, MD, MBA
- 9:05-9:30 Q&A

SESSION II: PRECLINICAL PIPELINE

- Moderator: **TBD**
- **9:30-9:40 BL-001 (drug candidate)** / **IrisRx platform** *Christopher Reyes, Bloom Sciences*
- 9:40-9:50 Name of Talk

9:50-10:00 Preclinical Data Supporting the Efficacy of OV329, A Next-Generation GABA Aminotransferase Inhibitor, Against Seizures Julia Tsai, PhD, Senior VP of Clinical Development and Medical Affairs, Ovid

10:00-10:15 Networking Break

SESSION III: PERSONALIZED MEDICINE: HOW FAR HAVE WE COME AND WHERE ARE WE GOING?

Moderator: **TBD**

- **10:15-10:20 Patient/Caregiver Perspective** Daniel Fischer, SCN1A
- **10:20-10:35** Specific gene mutation screening in infants; who are we finding and who are we missing? *Mark Fitzgerald, MD, PhD*
- **10:35-10:50** Gene based therapies: Why are they likely to succeed, why are they likely to fail? *Annapurna Poduri, MD, MPH*
- 10:50-11:10 Panel Discussion

SESSION IV: PIPELINE FOR GENE BASED THERAPIES

- Moderator: **TBD**
- **11:10-11:20** Behind the seizures program *Invitae*
- **11:20-11:30** NRTX-1001 (formerly NTX-101) inhibitory neuron cell therapy for drug-resistant temporal lobe epilepsy *Cory Nicholas, Neurona Therapeutics*
- **11:30-11:40 STK-001** *Kimberly Parkerson, Stoke Therapeutics*
- **11:40-11:50 NEUmiRNA Therapeutics: Aspiring to cure epilepsy** *Henrik Klitgaard, NEUmiRNA Therapeutics*
- **11:50-12:00 CODA Chemogenetic Receptor/Activator Drug** Susan Catalano, CODA Biotherapeutics, Inc.

- **12:00-12:10** Newly anticipated ASO therapeutic for a genetic target *Viet Nguyen, Biogen*
- 12:10-1:20 Networking Lunch (lunch on your own)

SESSION V: DIGITAL/DEVICE

Moderator: Robert Fisher, MD

- **1:20-1:30** Focused Ultrasound Foundation is an image guided, noninvasive, non-ionizing therapeutic technology *Vibhor Krishna, Focused Ultrasound*
- **1:30-1:40 EmbracePlus** *Matteo Lai, Empatica*
- **1:40-1:50 Epiminder** *Mark Cook, Cerebral Therapeutics*
- **1:50-2:00** Seer Long-Term At-Home Epilepsy Monitoring Dean Freestone, Seer Medical

2:00-2:10 Epihunter Absence *Dirk Loeckx, Epihunter*

- **2:10-2:20 Epilog wearable EEG sensor and REMI remote EEG monitoring platform** *Mark Lehmkuhle, Epitel*
- **2:20-2:30 24/7 EEG SubQ from UNEEG medical** *Lykke Blaabjerg, UNEEG Medical*
- 2:30-2:40 SeizeIT2 project Lauren Swinnen, KU Leuven
- **2:40-2:50 EpiCare@Home** *Benjamin Vandendriessche, Byteflies*
- 2:50-3:10 Networking Break

3:10-5:00 SHARK TANK COMPETITION

- 3:10-3:15 2021 Community Prize Winner Update: An Epilepsy Self-Management and Resilience Technical App (SMART) for Adolescents & their Community Deborah Koltai, PhD
- 3:15-3:20 2021 Investment Award Winner Update: Generalized Tonic-Clonic Seizure Detection with Video and Radar Tobias Loddenkemper, MD

Moderator / Emcee: Tom Stanton

Sharks:

Noah Richmond

Brandy Fureman, PhD, Chief Outcomes Officer, Epilepsy Foundation

David B. Moore, MD

Edward Hogan, MD

Kathryn Davis, MD

- **3:20** Introduction and Rules
- Finalists: Community Impact Award

An openscience community developing a smart connected patch to detect epilepsy seizures Clement Le Couedic, AURA Ngo

EpiPal: A patient and family-centered software platform for seizure detection, epilepsy safety and management, and treatment insights Amir Helmy, Epipal

Predictive Seizure Alert App Serge Lauriou / Helene Blanchard, My Medic Watch

Investment Award

Listen to the brain first, and then map it Pierre Wijdenes, PhD, Neuraura Biotech, Inc.

Novel therapies for epilepsy prevention Pavel Klein, PrevEP

Predictive analytics for brain surgery Max Sims / Brad Mahon, MindTrace Technologies, Inc.

6:00 ACCELERATOR AWARD RECEPTION & AWARD PRESENTATION

2022 MAY LIANG & JAMES LINTOTT SCHOLARSHIP

RECIPIENTS: Wesley Kerr, MD, PhD & Katie Ihnen, MD, PhD

2022 EPILEPSY FOUNDATION LIFETIME ACCELERATOR AWARD

RECIPIENT: Lynn Kramer, MD

Monday, June 6

- 7:00-8:00 Continental Breakfast and Registration
- 8:00-8:15 EF Digital Engine Laura Thrall, CEO, Epilepsy Foundation

SESSION VI: NEW TECHNOLOGY ADOPTION

- TBD Moderator: 8:15-8:20 **Patient/Caregiver Perspective** Noah Richmond 8:20-8:35 Name of Talk – Care Studio? Paul Muret, Google 8:35-8:50 Device patient focused design considerations and process Anouk van Westrhenen 8:50-9:20 Panel Discussion: Obtaining seizure data using remote monitoring/devices 9:20-9:35 **Reimbursement: Opportunities and Risks** Jo Ellen Slurzberg 9:35-9:50 **Economic models for payers** Ian Duncan 9:50-10:20 Panel Discussion: Reimbursement / Q&A 10:20-10:40 **Networking Break SESSION VII: DEVICES**
- Moderator: TBD
- **10:40-10:50** Nile Ai John Hixson, Nile

- **10:50-11:00** NextSense Brain Health Platform Jonathan Berent, NextSense
- 11:00-11:10 Epiness Oren Shriki, NeuroHelp
- 11:10-11:20 Name of Talk
- 11:20-11:30 Name of Talk
- 11:30-12:40 Networking Lunch (lunch on your own)

SESSION VIII: CREATING EQUITABLE AND INFORMATIVE TRIALS

- Moderator: Brandy Fureman, PhD
- **12:40-12:45 Patient/Caregiver Perspective** *Representative Iman Jodeh*
- **12:45-1:00** Genetic Epilepsies Etiologies or Syndromes? Elaine Wirrell, MD
- **1:00-1:15 Health equity in clinical trials** *Pamela S. Smith, PharmD, Pfizer*
- **1:15-1:30** Achieving patient focused drug development why are measure that are used, used? James Mitchell, MD, University of Liverpool
- 1:30-1:45 Basket Trials Kert Viele
- 1:45-2:15 Panel Discussion / Q&A
- 2:15-2:30 Networking Break

SESSION IX : CLINICAL DRUGS

- Moderator: Jacqueline French, MD
- **2:30-2:40 Rozanolixizumab (inhibitor of the neonatal Fc receptor (FcRn))** Stephen Yates, UCB Biosciences, Inc.
- 2:40-2:50 NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)

Brian Moseley, Neurocrine

2:50-3:00	Abi-009 surgically refractory epilepsy Jason Hauptman, Seattle Children's Hospital
3:00-3:10	ENX-101 Kimberly Vanover, Engrail
3:10-3:20	PRAX-562 Bernard Ravina, Praxis
3:20-3:30	Ganaxolone Joseph Hulihan, Marinus Pharmaceuticals, Inc.
3:30-3:40	XEN1101 Chris Kenney, Xenon
3:40-3:50	CT010 Valproate for ICV Administration Dan Abrams, Cerebral Therapeutics
3:50-4:00	LP352 Randall Kaye, MD, CMO, Longboard Pharmaceuticals
4:00-4:10	Darigabat Lilly Frohlich, Cerevel
4:10-4:20	Focal epilepsy study in patients with RNS devices <i>Ellen Schmidt, Lundbeck</i>
4:20-4:30	Staccato® alprazolam <i>Robert Roebling, UCB</i>
4:30-4:40	Radiprodil Pierandrea Muglia, Grin Therapeutics
4:40-4:50	ETX-020155 Mark Versavel, MD, PhD, MBA, Eliem
4:50-5:00	<mark>Name of Talk</mark> TBD, Neurelis
5:00	Closing Remarks

